Wednesday, October 22, 2025 7:08:50 PM
Thanks norisknorewards.
Briefing to Parliamentarians – October 2025
Meeting of the All-Party Parliamentary Group
on Brain Tumours (APPGBT)
Committee Room 17 HoC
18:00 – 19:15 Tuesday 21st October 2025
Agenda (following AGM which commences at 18:00)
• Welcome from Chair, Dame Siobhain McDonagh
• Apologies received
• Approval minutes from last meeting
• Matters arising from 9th September meeting
• Dan Knowles, CEO, Brain Tumour Research
• Sharon Kane, CEO, Neurochase
• Professor Keyoumars Ashkan MBE, Professor of Neurosurgery
and Lead Clinician for Neuro-Oncology at King’s College Hospital,
and Chair of King’s Neurosciences Clinical Trial Unit
• Dr Nicky Huskens, CEO, Tessa Jowell Brain Cancer Mission
• AOB and next meeting
Briefing to Parliamentarians – October 2025
Meeting of the All-Party Parliamentary Group
on Brain Tumours (APPGBT)
Committee Room 17 HoC
18:00 – 19:15 Tuesday 21st October 2025
Agenda (following AGM which commences at 18:00)
• Welcome from Chair, Dame Siobhain McDonagh
• Apologies received
• Approval minutes from last meeting
• Matters arising from 9th September meeting
• Dan Knowles, CEO, Brain Tumour Research
• Sharon Kane, CEO, Neurochase
• Professor Keyoumars Ashkan MBE, Professor of Neurosurgery
and Lead Clinician for Neuro-Oncology at King’s College Hospital,
and Chair of King’s Neurosciences Clinical Trial Unit
• Dr Nicky Huskens, CEO, Tessa Jowell Brain Cancer Mission
• AOB and next meeting
Professor Ashkan will present on DCVax, a precision personalised immune
therapy for brain tumours. He will address the exceptionally comprehensive
review by the Medicines and Healthcare products Regulatory Agency
(MRHA) ahead of market authorisation that has been ongoing for over a year.
“The review process is expected to conclude in the next couple of months,
and the brain tumour community anxiously looks forward to the outcome given
the extremely poor patient prognosis and the lack of meaningful progress in the
field for the past 20 years.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
